These results are consistent with and provide a mechanism to the inverse correlation between ER signaling and antigen presentation that was seen in the recent analysis of a clinical trial of chemotherapy in combination with pembrolizumab in metastatic HR+ breast cancer (13). This evidence concerns the gene ESR1 and breast carcinoma.